Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Thoracic Malignancies
•
Medical Oncology
How would you treat a patient with progressive ALK (+) NSCLC that has MET Exon 14 deletion upon repeat molecular testing on metastatic site?
Related Questions
Would a patient with a resected NSCLC mass under 3 cm, without lymph node involvement or distant metastases, but with visceral invasion identified on pathology, benefit from adjuvant therapy?
Under what circumstances, if any, would you wait on initiating a TKI for metastatic recurrence of a Stage III NSCLC which occurred while on consolidative durvalumab to minimize pneumonitis risk?
How do you determine your next line of therapy In ALK+ metastatic NSCLC patients who have widespread progression on first-line lorlatinib?
Is DLL3 expression necessary for tarlatamab efficacy in small cell lung cancer?
Are you planning to start running IHC HER2 testing on all tumor types, even those where HER2 overexpression is less typical, in light of tumor agnostic approval of trastuzumab deruxtecan?
Can Dupixent and Durvalumab be used at the same time in a patient with extensive stage small cell lung cancer?
In patients with stage III NSCLC who experience locoregional recurrence after neoadjuvant chemoimmunotherapy, surgery, and maintenance immunotherapy, and are treated with definitive chemoradiation at recurrence—what is the optimal systemic therapy strategy post-chemoradiation?
Would you change systemic therapy in a patient with SCLC with stable systemic disease but CNS progression?
When will you choose Tarlatamab over an alternative systemic therapy (e.g. lurbinectedin, topotecan) for relapsed ES SCLC?
Would you give durvalumab consolidation to a patient with stage III NSCLC with an STK11 mutation?
